Akeso's Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting
Portfolio Pulse from
Akeso Inc. presented promising phase III results for cadonilimab, a PD-1/CTLA-4 bispecific antibody, in treating locally advanced cervical cancer. The COMPASSION-18 study demonstrated a 100% overall response rate, with 84.8% complete response and a 74.9% 12-month progression-free survival rate. The treatment showed a favorable safety profile with no treatment-related deaths.
March 21, 2025 | 3:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cadonilimab's remarkable performance in cervical cancer treatment could significantly boost Akeso's market position and future drug development prospects.
Exceptional clinical trial results with 100% response rate and favorable safety profile suggest strong potential for drug approval and commercial success, which could positively impact Akeso's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100